Skip to main content

Table 2 Overall and progression-free survival of patients in the two treatment groups

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Group OS (months) P PFS (months) P
Median 95% CI Median 95% CI
Sorafenib 18 11.797–24.203 0.223 6 3.270–8.730 0.004
TACE + sorafenib 22 14.095–29.905 8 3.400–12.600
  1. CI confidence interval, OS overall survival, PFS progression-free survival